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IL-10, IL-6, and TNF-a: Central factors in the altered cytokine
network of uremia—The good, the bad, and the ugly. It has been
increasingly apparent that wasting and cardiovascular disease
(CVD) is associated with a persistent systemic inflammatory
response in end-stage renal disease (ESRD) patients. The rea-
sons for the increased risk of inflammation in ESRD patients
appear to be complex, including nondialysis as well as dialysis-
related factors. The combination of an impaired immune re-
sponse coupled with persistent immune stimulation may have
a role in the low-grade systemic inflammation and altered cy-
tokine balance that characterizes the uremic state and which
may translate into increased risk for vascular disease. The ac-
celerated atherosclerotic process of ESRD may involve several
interrelated processes, such as oxidative stress, endothelial dys-
function, and vascular calcification, in a milieu of constant low-
grade inflammation with impaired function of neutrophils and
T cells, as well as a dysregulated cytokine network. Although
a large number of pro- and anti-inflammatory cytokines are of
importance, available data suggest that the anti-inflammatory
cytokine interleukin (IL)-10 and the mainly proinflammatory
cytokines IL-6 and tumor necrosis factor-a (TNF-a) may play
important roles in the development of Th imbalance, CVD and
wasting in the uremic milieu. Given the strong association be-
tween proinflammatory cytokines and complications common
in ESRD, such as vascular calcification and wasting, the poten-
tial role of both general and targeted anticytokine treatment
strategies in ESRD patients needs further evaluation.
The introduction of chronic hemodialysis by among
others Dr Belding Scribner (who is credited for develop-
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ing the first permanent access [1] and for establishing the
first chronic dialysis unit in the early 1960s), as a means
for the treatment of patients with end-stage renal dis-
ease (ESRD) was, indeed, a major advance in modern
medicine. However, already 30 years ago it was recog-
nized that patients with ESRD were not cured by dialysis
and, among many other complications, were at marked
risk for atherosclerotic cardiovascular disease (CVD) [2].
To this date, the high CVD-related mortality remains
the major cause of premature deaths in ESRD patients,
despite major technologic improvements in dialysis and
an increased focus on improving small solute clearances.
However, the recent HEMO [3] and ADEMEX [4] stud-
ies indicate that increased small solute clearances over
and above those applied in current clinical practice do
not necessarily result in improved survival, thus indicat-
ing that “dialysis adequacy” is more than Kt/V urea. In-
deed, to improve the abysmal survival of ESRD patients,
the heart of the matter is really to identify which fac-
tors that may explain why there is such a discrepancy
between the vascular and chronologic age of the uremic
patient [5]. Although nonatherosclerotic CVD may be an
important contributor to the high cardiovascular mortal-
ity rate in ESRD, it has been suspected that ESRD pa-
tients are also subject to an accelerated atherosclerotic
process, a proposal difficult to prove in clinical studies.
However, studies performed on partially nephrectomized
apolipoprotein E (ApoE)-deficient mice have demon-
strated that the uremic milieu per se may accelerate
atherogenesis [6]. Much of the increased risk may be at-
tributable to the observation that the two major causes
of ESRD in the United States are diabetes and hyper-
tension, conditions known to predispose patients to in-
creased CVD-related mortality. However, the extent and
severity of cardiovascular complications is clearly dispro-
portionate to the presence of classic risk factor profile,
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and traditional risk factors alone may not predict cardio-
vascular outcome in this patient population.
The search for nontraditional risk factors that may be
involved in the pathogenesis of CVD in the patient with
chronic kidney disease (CKD) has been an area of intense
study. During the last few years chronic inflammation has
become recognized as a major culprit in a whole range of
pathologic states, such as CVD, obesity, diabetes, malnu-
trition, and even aging [7]. In this regard, it is becoming
increasingly appreciated that ESRD is characterized by a
state of chronic inflammation that seems to be linked with
oxidative stress, endothelial dysfunction, vascular calcifi-
cation, and wasting [8, 9]. Indeed, a wide array of inflam-
matory biomarkers, such as C-reactive protein (CRP),
interleukin (IL)-6, and white blood cell count, are robust
predictors of outcome in ESRD patients [10].
The reason for the increased risk for chronic inflamma-
tion in ESRD patients appears to be complex [10]. The
impaired immune response in uremia and the impaired
function of neutrophils and T cells in patients with ESRD
translate into increased risk for infection [11]. The gen-
eral defect in cell-mediated immunity in the ESRD pa-
tient results in not only increased risk for infection, but
also a higher incidence of cancer [12]. While defensive
responses are impaired, the immune system is also under
constant stimulation, due to the process of dialysis itself.
Repeated opportunities for organisms to enter the circu-
lation and/or peritoneal cavity during the dialysis proce-
dure can contribute to activation of leukocytes as well as
the exposure to dialysis membranes [13]. Also, a num-
ber of uremic retention solutes, such as guanidine com-
pounds, exert pro- as well as anti-inflammatory effects on
monocyte/macrophage function, which could contribute
to both CVD and the propensity to infectious complica-
tions in this patient group [14]. Furthermore, alterations
in Ca × PO4 metabolism increase the risk for vascular
calcification, which may act as a yet another nidus for
a local inflammatory response [15]. The combination of
an impaired immune response coupled with persistent
immune stimulation may have a role in the low-grade
systemic inflammation and altered cytokine balance that
characterizes the uremic state and which may translate
into increased CVD risk.
Clearly, the immune system is extremely complex and
amazingly important for maintaining perfect health. Al-
though we fully recognize that a plethora of cytokines
(such as IL-1 and IL-18) are of importance in the com-
plex cytokine network, we will concentrate this review
on three central cytokines that are dysregulated in the
uremic milieu and appear to influence the risk for CVD
and wasting in this population. Like the characters in the
Clint Eastwood Western movie from the 1960s The Good,
the Bad and the Ugly, the roles of these three cytokines
and their soluble receptors are quite different. Whereas
the first cytokine that will be discussed, IL-10 (the good
one) appears to have a critical role in suppressing the in-
flammatory response the other two cytokines, IL-6 (the
bad one) and tumor necrosis factor-a (TNF-a) (the ugly
one), seem to have proinflammatory and proatherogenic
properties (Fig. 1). It should be emphasized that all three
cytokines have vital functions and lacking any of these
agents would likely be detrimental to the host, Clint
Eastwood not withstanding. In this review we will also
pinpoint the putative associations between cytokine dys-
regulation and vascular calcification, an emerging cardio-
vascular risk factor. Finally, we will discuss the potential
future role for general and targeted anticytokine thera-
peutics in this patient group.
IL-10: THE GOOD ONE
IL-10 (18 kD) is a product of immunoactive cells,
mainly monocytes and lymphocytes, that has been re-
garded as one of the most important anti-inflammatory
immune-regulating cytokines. The secretion of IL-10 is
delayed and always follows that of proinflammatory fac-
tors with a latency of a few hours. The coupling of ag-
gressive inflammatory factors with the delayed secretion
of IL-10 ensures that any inflammatory response will se-
curely be down-regulated after some time. IL-10 may act
in an auto- or paracrine manner on the localized inflam-
matory response or in a more hormonal fashion on the
systemic level of inflammation. Exclusive induction of
IL-10 without preceding secretion of proinflammatory
cytokines seems to be a rare event. In ESRD patients,
the most relevant production of IL-10 seems to occur
in monocytes and macrophages. Typical stimuli leading
to its production are endotoxins and activated comple-
ment fragments, agents known to mediate bioincompat-
ibility reactions during renal replacement therapy. Thus,
dialysis treatment may contribute to the overall level of
the long-acting cytokine, although relevant modification
of IL-10 plasma levels by a single dialysis session does
not seem to occur. The cytokine may as well be induced
by catecholamines or TNF-a [16] linking its production
to stress reaction and inflammation. As IL-10 is mainly
cleared through the kidneys, probably by glomerular fil-
tration (Fig. 2) and tubular metabolism, its plasma half-
life is markedly increased in ESRD leading to elevated
plasma levels [17]. Furthermore, uremic monocytes pro-
duce higher amounts of this cytokine compared to those
of healthy individuals [18], probably a consequence of
chronic monocyte activation in uremic patients.
It is notable that although IL-10 effectively down-
regulates proinflammatory cytokines, such as IL-1, IL-
6, and TNF-a, its effects are not confined to these me-
diators. In fact, IL-10 also reduces the production of
chemotactic factors, such as IL-8 or CC chemokines, that
may attract further leukocytes to the location of inflam-
matory activity [19]. Moreover, the expression of major
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Fig. 1. Potential mechanisms by which pro- and anti-inflammatory cytokines may promote accelerated atherosclerosis, other uremic complications,
and wasting. TNF-a is tumor necrosis factor-a; IL is interleukin.
histocompatibility complex (MHC) class II molecules
and adhesion molecules, being responsible for the inter-
action between monocytes and lymphocytes during im-
mune activation, is down-regulated as well [20]. Although
IL-10 binds to a heterodimer receptor complex, which in-
hibits the nuclear translocation of nuclear factor-kappaB
(NF-jB) [21] the mechanism(s) by which IL-10 interacts
with so many different structures is only partially under-
stood.
Similar to most other cytokine genes, polymorphic se-
quences have been described in the IL-10 promoter. The
most relevant ones are the microsatellites 1.2 kB and 4 kB
upstream of the transcription start site and the point mu-
tations at positions –1082 (G/A), −819 (C/T), and –592
(C/A) [22]. Unlike many other cytokines, these genetic
variations are associated with different levels of stimu-
lated IL-10 production [22], a finding confirmed also in
uremic patients [23]. In particular, carriers of the homozy-
gous allele G/G at position –1082 of the IL-10 promoter
produce 30% more of the cytokine with a definite stimu-
lus than carriers of the allele A/A. While IL-10 levels are
elevated in uremia, it is becoming increasingly evident
that subjects with the highest IL-10 levels have better im-
mune balance. Specifically, it is known that subjects with
ESRD often have an impaired immune response to vac-
cines, particularly the hepatitis B vaccine [24]. However,
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Fig. 2. Inverse correlation between glomerular filtration rate and cir-
culating interleukin-10 levels in a group of 151 end-stage renal disease
patients starting dialysis treatment in Stockholm, Sweden.
recent studies suggest that the immune response to hep-
atitis B vaccine is better in subjects with the highest IL-10
levels or with the genotype associated with higher IL-10
levels [25]. The mechanism may relate to both suppres-
sion of the chronic inflammatory response and redirec-
tion of T cells toward a normal humoral response.
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Table 1. Putative mechanisms by which interleukin (IL)-10, IL-6, and tumor necrosis factor-a (TNF-a) may influence the atherosclerotic process
and nutritional status
Cytokine Atherosclerotic process Catabolic effects
IL-10 Down-regulation of adhesion molecules –
Down-regulation of proinflammatory cytokines –
Inhibition of O2− production –
Reduction of metalloproteinase production –
Inhibition of chemotactic proteins –
IL-6 Up-regulation of adhesion molecules Promotes muscle protein breakdown
Decreases adiponectin expression Inhibition of insulin-like growth factor-1
Down-regulation of chemokine production Decreases appetite
Causes endothelial dysfunction –
TNF-a Down-regulation of apolipoprotein E Promotes muscle protein breakdown
Promotes vascular calcification Suppression of MyoD
Causes endothelial dysfunction Activates the ubiquitin proteasome system
Stimulates NADPH oxidative pathways Decreases appetite
Mediates insulin resistance –
NADPH is nicotinamide adenine dinucleotide phosphate.
IL-10 as an antiatherosclerotic cytokine
The recent interest in IL-10 as a potentially protec-
tive cytokine in the atherosclerotic process is based on
the hypothesis that the development of plaque-forming
atherosclerosis is a localized inflammatory process of
the vascular wall [26]. Indeed, IL-10 may act as an an-
tiatherogenic factor by a number of different mechanisms
apart from mere inhibition of proinflammatory cytokines.
First, IL-10 interferes with the first step in atherogene-
sis by inhibiting attachment of circulating immune cells
to the endothelium through down-regulation of the ad-
hesion molecules CD18, CD60L, and intercellular adhe-
sion molecule-1 (ICAM-1) [27]. Second, IL-10 inhibits
the secretion of chemotactic proteins by macrophages
that might attract further leukocytes to the location of
subendothelial inflammation [19]. Moreover, IL-10 re-
duces the production of lytic enzymes produced by mono-
cytes, such as matrix-metalloproteinases (enzymes asso-
ciated with destabilization of a plaque), and suppresses
superoxide anion production [28], suggesting that IL-10
could prevent plaque destabilization [29]. In view of these
combined effects, IL-10 could theoretically be regarded
as a “good” antiatherosclerotic cytokine (Table 1). In-
deed, animal experiments confirm such antiatheroscle-
rotic effects of the over-expression of IL-10 in low-density
lipoprotein (LDL) receptor knockout mice, which other-
wise develop a rapidly progressive atherosclerosis within
a few weeks [30].
However, clinical studies on the anti-atherosclerotic
effect of IL-10 have been controversial. Whereas two
studies reported lower plasma levels of IL-10 in patients
with unstable angina pectoris [31, 32] another study [33]
could not confirm these findings. This approach may not
be very reliable and definitely does not negate the cy-
tokine’s antiatherogenic potential in humans. Since most
of the effects of IL-10 may act locally within the vascular
wall, studies on circulating IL-10 levels may not be able
to detect them. As an experimental approach, it might be
more interesting to determine the number of IL-10 pro-
ducing monocytes in blood or the atherosclerotic plaque
rather than the amount of cytokine that leaked into the
circulation. This evaluation has not been made in larger
clinical studies. The relevance of IL-10 for CVD may also
be derived from genetic studies. In hemodialysis patients,
an IL-10 promoter polymorphism is associated with car-
diovascular mortality (i.e., IL-10 “low-producer” patients
have a significantly enhanced risk of death due to CVD
compared to IL-10 “high-producers”) [34]. These find-
ings may be another indication of the antiatherosclerotic
effect of IL-10 at least in high-risk ESRD patients. How-
ever, until now, attempts to assign a particular risk to the
IL-10 genotype in the general population have failed [35].
It is not yet clear whether the association does not exist in
individuals with normal renal function or if study designs
and sample sizes have been insufficient to detect an asso-
ciation on the background of a much lower overall risk
compared to ESRD patients. One further important re-
sult of the genetic studies is that the predisposition to high
secretion of IL-10 is predictive only for a reduced car-
diovascular mortality. This anti-inflammatory cytokine
is, on the other hand, associated with diminished anti-
infectious properties, which may be an important caveat
for anti-inflammatory therapeutic strategies.
IL-6: THE BAD ONE
Although a number of pro- and anti-inflammatory cy-
tokines orchestrate the inflammatory response, IL-6 is a
particularly interesting molecule since it has both pro-
and anti-inflammatory effects. The IL-6 system promotes
inflammatory events through the activation and prolif-
eration of lymphocytes, differentiation of B cells, leuko-
cyte recruitment, and the induction of an acute phase
protein response in the liver. IL-6 (22 to 27 kD) is
produced by numerous types of immune cells, including
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Table 2. Factors that may be associated with increased circulating
interleukin (IL)-6 and tumor necrosis factor-a (TNF-a) levels in
end-stage renal disease (ESRD) patients
Genetic factors (such as single nucleotide polymorphisms)
Old age
Decreased renal function and retention of uremic solutes
Comorbidity
Volume overload/chronic heart failure
Persistent infections
Chlamydia pneumoniae
Catheter infections
Peridontitis
Oxidative stress
Increased visceral fat mass
Dialysis-related factors
Bioincompatibility
Nonsterile dialysate
Backfiltration
monocytes, mesothelial cells, fibroblasts, adipocytes, and
lymphocytes usually in response to physiologic stimuli,
such as TNF-a, IL-1b , bacterial endotoxins, physical ex-
ercise, and oxidative stress. IL-6 acts on target cells via
complex receptor system composed of a ligand binding
subunit (IL-6R or gp 80) and a signal transducing subunit
(gp 130). After IL-6 binds to IL-6R, this complex trig-
gers the dimerization of the signal-transducing receptor
component gp 130 [36]. Soluble forms of both receptor
components are generated by shedding and are found in
plasma. They have been shown to be important regula-
tors of IL-6 activity, and sIL-6R provides an important
signaling pathway intimately involved in the transition
between the early and late phase of the inflammatory re-
sponse [37]. Whereas most other cytokines function via
paracrine/autocrine mechanisms, the major effects of IL-
6 are a consequence of its presence in the circulation and
can take place at sites distinct and distant from its ori-
gin. The combination of both distant and local effects
may be one reason why IL-6 could be considered a “bad”
cytokine that may promote atherosclerosis and muscle
wasting (vide infra). IL-6 can be detected in the 1 pg/mL
range in healthy individuals, and is elevated in most, but
not all, ESRD patients [38].
Causes of elevated IL-6 in CKD
The causes of elevated plasma IL-6 levels in ESRD
patients may be related to a multitude of different fac-
tors (Table 2). Even before the initiation of dialysis ther-
apy, patients with decreased renal function demonstrate
signs of inflammation. We [39] and others [40] have found
relationships between renal function and various inflam-
matory biomarkers, such as CRP, IL-6, and TNF-a, sug-
gesting that the kidney play a role in the clearance of
pro-inflammatory cytokines. Indeed, studies in rats have
shown that the kidney is the main site of metabolic degra-
dation of IL-1b [41]. Moreover, a clinical study in ESRD
patients have shown that serum creatinine is a major de-
terminant of plasma IL-6 levels [42].
Although decreased elimination may be a major cause
of elevated IL-6 levels in ESRD patients increased cy-
tokine generation also may play a role. Indeed, both
fluid overload and congestive heart failure (CHF) may
contribute to increased IL-6 levels as renal function de-
clines. Clinical studies have shown that circulating levels
of proinflammatory cytokines, such as TNF-a and IL-6,
are increased in CHF patients and correlate with func-
tional status [43] and that local and systemic effects of
proinflammatory cytokines may have an important role
in its pathogenesis [44]. It has also been reported that
changes in IL-6 and CRP are dynamic and that increased
levels occur mainly with uncompensated CHF [45]. Al-
though accumulating data suggest that various persis-
tent infections, such as Chlamydia pneumoniae, are as-
sociated with atherosclerosis and cardiovascular events,
these associations may in large part be attributable to
traditional risk factors [46]. However, as polymorphic
membrane proteins of C. pneumoniae have recently been
shown to induce IL-6 production in endothelial cells [47],
this may be one mechanism by which chlamydial infec-
tion contributes to the process of vascular injury during
the development and progression of atherosclerotic le-
sions. This hypothesis is supported by clinical studies that
showed an association between serologic evidence of per-
sistent chlamydial infection, carotid atherosclerosis and
elevated IL-6 in ESRD patients [48, 49]. Several genetic
variations within the IL-6 gene promoter region have
been identified, which are associated with alterations in
plasma levels or expression, such as the −174G/C single
nucleotide polymorphism (SNP). Although this SNP has
been associated with longevity in nonrenal patients [50]
and kidney allograft survival [51], we do not know if this
SNP is associated with phenotype and outcome in ESRD
patients.
In addition to nondialysis related factors, it seems rea-
sonable to suggest that the dialysis procedure per se
represents additional stimulation of the inflammatory re-
sponse. Indeed, Takahashi et al [52] demonstrated that
both hemodialysis and peritoneal dialysis generates an
increase in blood mononuclear cell IL-6 mRNA expres-
sion and plasma IL-6 levels. Caglar et al [53] showed
that circulating IL-6 levels increased following hemodial-
ysis, providing evidence of hemodialysis-induced de-
layed inflammatory response. Several factors related to
hemodialysis have been proposed to contribute to the
generation of IL-6 and/or enhance the inflammatory ef-
fect of IL-6, specifically use of bioincompatible mem-
branes and nonsterile dialysate [10]. Finally, as many
cytokine encoding genes are also expressed in adipocytes
it has been estimated that the adipose tissue may ac-
count for as much as 20% of systemic IL-6 concen-
trations [54]. Thus, visceral adiposity may be yet an-
other reason for elevated IL-6 levels in ESRD patients
[55].
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IL-6 as a proatherogenic cytokine
Plasma IL-6 level has been found to correlate with in-
creased mortality and poor outcome in ESRD patients
[56–58] consistent with studies relating IL-6 to mortality
in the elderly [59] and in healthy men at risk for my-
ocardial infarction [60]. Based on findings that injection
of recombinant IL-6 exacerbates early atherosclerosis
in ApoE-deficient mice [61], it has been suggested that
IL-6 may have independent proatherogenic properties
(Table 1). Consistent with this hypothesis, elevated IL-6
levels have been associated with progression of carotid
atherosclerosis in patients with ESRD [48]. The fact
that IL-6 promotes production of CRP, a protein known
to decrease endothelial nitric oxide synthase (eNOS)
expression [62], may be a reason why IL-6 has been re-
ported to contribute to the development of atherosclero-
sis through various metabolic, endothelial and coagulant
mechanisms [63]. Nawawi et al [64] reported that both
IL-6 and serum ICAM-1 reflect endothelial dysfunction
in a nonrenal patient population. As IL-6 and its solu-
ble receptor decrease adiponectin (an antiatherogenic
adipokine) mRNA in vitro [65], this could provide yet
another mechanism by which IL-6 promotes atheroscle-
rosis. Further support for the proatherogenic effect of
IL-6 may be derived from a study showing that increased
IL-6 expression is involved at the fibrous plaque stage of
the atherosclerotic process [66].
IL-6 is associated with aging and wasting
Muscle wasting (sarcopenia), which occurs with nor-
mal aging, is usually much more pronounced in ESRD
patients. As weight loss is such a common feature of
many inflammatory disorders, it has been suggested that
subclinical inflammation is an important component of
the pathophysiology of muscle wasting [67]. Recent ev-
idence suggests a possible role for IL-6 in this process.
Indeed, IL-6 stimulates the breakdown of muscle protein
[68] and promotes cancer-related wasting [69]. Moreover,
IL-6 receptor antibody has been shown to inhibit muscle
atrophy that occurs in IL-6 transgenic mice [70]. As IL-6
also inhibits the secretion of insulin-like growth factor
(IGF-1), reduced IGF-1 signaling may also be involved
in the sarcopenic process [71].
IL-6 has been particularly linked to the muscle wasting
that occurs in the elderly [72]. Aging is associated with
increased IL-6 production and a dysregulation of inflam-
matory cytokines [73], which may be related to aging-
related loss of sex hormones (particularly testosterone)
that act to suppress IL-6 expression [67]. Interestingly,
genetic factors may also contribute to the muscle wasting
seen with high age and individuals who are genetically
predisposed to produce high IL-6 levels during aging are
disadvantaged for longevity [50]. Thus, IL-6 may be a
key cytokine involved in the process of aging and frailty
(Fig. 3). The close association between muscle wasting
(evaluated by thigh muscle area) and IL-6 in long-term
hemodialysis patients provides evidence that IL-6 may be
associated with muscle wasting also in renal patients [74].
However, as proposed by Dinarello and Roubenoff [75],
cytokines may play a decreasing role in the pathogenesis
of loss of muscle mass as muscle wasting increases and
curtails the synthesis of cytokines, which can be viewed
as a protective mechanism. Proinflammatory cytokines,
such as IL-6, may also cause malnutrition either by in-
creased protein catabolism or by affecting appetite and
eating behavior. Indeed, Kalantar-Zadeh et al [76] have
demonstrated that anorexia in hemodialysis patients is
associated with higher levels of IL-6. Although it has
been speculated that a continuous immune stimulus, as
in chronic infections, can enhance leptin secretion by the
activation of IL-6, the mechanism(s) of cytokine-induced
anorexia are not clear. Whereas it seems clear that admin-
istration of cytokines increases leptin mRNA levels in an-
imal models [77], data regarding the association between
inflammation and leptin in ESRD patients are conflicting.
TNF-a: THE UGLY ONE
TNF, a proinflammatory cytokine (17 kD) originally
associated with killing of tumor cells, has a pivotal role
in regulating both pro- and anti-inflammatory mediators.
TNF-a has been regarded a “master regulator” of the cy-
tokine cascade that provides a rapid form of host defense
against infection but is fatal in excess. TNF is highly multi-
functional with effects on lipid metabolism, coagulation,
insulin resistance, and endothelial dysfunction (Table 1).
The major cellular origin of TNF-a, previously known as
cachectin, is activated macrophages. It should be noted
that whereas IL-6 is strongly associated with CRP and
other inflammatory biomarkers the association between
TNF-a and CRP is rather weak. This suggests that circu-
lating levels maybe influenced by a number of different
factors and that circulating TNF-a levels may not reflect
biologic activity at the tissue levels.
Causes of elevated TNF-a in CKD
In uremia, deterioration of renal function may be one
of the most important factors associated with a signifi-
cant increase in TNF-a activity [78]. Indeed, correlations
between renal function and TNF-a and its soluble re-
ceptors have been demonstrated in patients with varying
degrees of renal failure [40]. Further, reduced renal func-
tion has been shown to affect TNF-a clearance in rats
[79]. The importance of the kidney in TNF-a handling is
further underscored by the findings of Hession et al [80],
which demonstrated that the Tamm-Horsfall glycopro-
tein might regulate TNF-a activity. However, since the
half-life of TNF-a is short and local tissue degradation
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Fig. 3. Proposed changes in body distribution (muscle mass and fat mass) and the atherosclerotic process in relation to interleukin-6 with increasing
age in normal physiologic aging (top) and accelerated aging (bottom) observed in patients with wasting disorders, such as end-stage renal disease
(ESRD), malignancy, congestive heart failure (CHF), rheumatoid arthritis (RA), and acquired immunodeficiency syndrome (AIDS). GFR is
glomerular filtration rate; ICAM-1 is intercellular adhesion molecule-1; IL is interleukin.
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may also contribute to inactivation of cytokines, more re-
search is needed to determine the relative importance of
the kidney in TNF clearance. Other putative causes of
elevated circulating TNF-a levels in the ESRD patient
may include factors, such as insulin resistance, volume
overload, and obesity (Table 2).
TNF-a is associated with catabolism
Cachexia is usually associated with elevated concen-
trations of TNF-a in older patients without renal disease
[81]. Surrogate markers of malnutrition and anorexia
have been associated with elevated levels of TNF-a also
in dialysis patients [82]. TNF-a may mediate catabolism
through several mechanisms (Table 1). One important
mechanism is increased protein hydrolysis and muscle
protein breakdown. TNF-a has been shown to activate
the transcription factor NF-jB to suppress MyoD mRNA
at the posttranscriptional level, thus disrupting skeletal
muscle differentiation and repair of damaged muscle tis-
sue [83]. A decrease in muscle mass may also be caused
by activation of the ubiquitin proteasome proteolytic sys-
tem, which accelerates degradation of muscle protein
[84]. Since TNF-a increases ubiquitin gene expression in
skeletal muscle, it is possible that it causes muscle wasting
by stimulating protein catabolism via the ubiquitin pro-
teosome pathway [85]. A second important mechanism
for the proposed cytokine-induced malnutrition is the ef-
fect of proinflammatory cytokines on appetite and eating
behavior. The mechanism of cytokine-induced anorexia
is not clear, although some studies have implicated a role
for leptin. Grunfeld et al [77] found that administration
of TNF-a increased leptin mRNA levels in hamsters and
noted a strong inverse correlation between leptin mRNA
level and subsequent food intake.
TNF-a: A proatherogenic cytokine?
Although available evidence suggests up-regulated
TNF-a system activity in ESRD patients [57] data linking
elevated circulating TNF-a levels to CVD and mortality
have not been as clear as for IL-6. However, we [86] have
found a weak, but significant, association between TNF-
a levels and the presence of carotid plaques in ESRD
patients. Further, Kimmel et al [57] have reported that
elevation of TNF-a level predicted death in dialysis pa-
tients, even after controlling for age and serum albumin
level. Thus, further studies are needed to establish the
independent role of TNF-a in uremic atherogenesis. Al-
though there is still no definite proof of an association
between TNF-a and cardiovascular mortality in ESRD
there is many reasons to believe that TNF-a may have
“ugly” properties that promote atherogenesis (Table 1).
In fact, TNF-a has been shown to down-regulate ApoE
(important in the metabolism of intermediate-density
lipoprotein) secretion [87], promote in vitro calcification
of vascular cells [88], increase nicotinamide adenine din-
ucleotide phosphate (NADPH) oxidase pathways [89]
and mediate endothelial dysfunction [90]. A recent study
has shown strong associations between TNF-a and en-
dothelial dysfunction in coronary artery disease (CAD)
patients [91]. Moreover, the increased adipose tissue ex-
pression of TNF-a indicates that this cytokine may be
directly linked to insulin resistance [92]. As it has been
suggested that TNF-a may be a link between hyper-
triglyceridemia and inflammation in systemic lupus ery-
thematosus (SLE) [93], further studies are also needed
to investigate the role of TNF-a in insulin resistance and
dyslipidemia of the uremic patient. The failing heart pro-
duces large quantities of TNF-a and a direct relationship
has been shown between the level of TNF-a expression
and the CHF severity [94]. TNF-a has also been thought
to be an important cytokine involved in CHF. In a study
by Rauchhaus et al [95] serum TNF-R1 was the strongest
and most accurate predictor of cardiac failure, indepen-
dent of other markers of CHF severity.
CYTOKINE IMBALANCE IN RENAL DISEASE
There is a vast literature on cytokine alterations in
ESRD patients (with or without renal replacement ther-
apy) all reporting elevated, but markedly divergent,
concentrations of both IL-6 and TNF-a. Most of the pub-
lished work concentrates on a few cytokines that were
measured in plasma, culture supernatants, or in asso-
ciation with circulating cells. These studies provided a
sound body of information on the chronic inflammation
of renal disease. However, they do not take into account,
that many, if not all, cytokines are counterbalanced by
inhibitors or other cytokines with contrary effects. The
way we gained much of our knowledge on cytokine ac-
tion, namely by incubating cells with cytokines in vitro,
still guides our thinking. However, this may be mislead-
ing for two reasons. First, cytokines do not exhibit their
effects as a single substance that takes action on a def-
inite cell type. Elevation of one cytokine immediately
leads to up- or down-regulation of several others. One
might therefore think of the cytokine network as a spider
web in which movement of one knot leads to the move-
ment of many others (Fig. 4). The second misconception
is that many of the effect of cytokines are local, not sys-
temic. Thus, as a significant proportion of the effects are
paracrine and very hard to detect, there is good reason to
be restrictive with the interpretation of plasma cytokine
measurements.
CKD may be a valid model to illustrate the cy-
tokine network hypothesis. Proinflammatory cytokines
are counterbalanced at several levels. First, the secretion
of IL-1b is linked to the secretion of the IL-1 receptor
antagonist (IL-1RA), which binds the cytokine and pre-
vents its actions. Although many studies relied on IL-1b
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Fig. 4. Simplified sketch of the interactions between pro- and anti-
inflammatory cytokines and their inhibitors. Modifications of one factor
in the network leads to compensatory alterations in many others, prob-
ably with the intention to make all activations temporary and regain a
physiologic balance. IL is interleukin; TNF is tumor necrosis factor.
measurements to draw conclusions about proinflamma-
tory activation, the balance between IL-1b and IL-1RA
might be a more valid parameter, since the secretion of
IL-1RA is as quickly modulated as that of IL-1b itself
[96]. The same mechanism also applies to TNF-a, which
is counterbalanced by soluble TNF receptors [40]. One
might hypothesize that the production of active cytokines
and specific inhibitors is a mechanism that allows the
mediators to act locally while preventing them from act-
ing systemically. Once again, plasma levels of cytokines
should be interpreted with caution, in particular since
many established immunoassays could not distinguish be-
tween active proteins and those that are blocked by their
specific inhibitors. The second level of cytokine balanc-
ing is a functional one. Proinflammatory mediators are
counterregulated by anti-inflammatory cytokines, such as
IL-10. All stimuli that induce proinflammatory activation
in immunocompetent cells also induce IL-10, which ulti-
mately limits the production of inflammatory cytokines
and shuts them down. Thus, IL-10 governs the level of in-
flammation that is allowed in response to a definite stim-
ulus [25]. There is a tight regulatory circle between both
types of cytokines which leads to the negative correlation
between the secretion of TNF-a and IL-10 [25]. Evalua-
tion of cytokine regulatory systems is complicated by the
high interindividual genetic variation of plasma cytokine
levels. Nevertheless, at least for IL-10, there are groups
of individuals who on average produce more or less of
the cytokine. The IL-10 promoter polymorphisms ex-
plain these interindividual differences and patients with
the IL-10 high producer genotypes tend to secrete more
of the cytokine than those with the low producer geno-
type. Clearly, these differences may translate to a differ-
ent overall level of chronic inflammation in ESRD [23]
as well as to different risks of inflammation-associated
CVD [34]. Finally, it should be mentioned that different
binding proteins, such as a2-macroglobulin, may serve as
extracellular cytokine reservoirs and protective shields
against degradation of cytokines [97] and that various
molecular suppressors of cytokine signaling (SOCS) may
have essential roles in vivo in the negative regulation of
cytokines [98].
Altered T-helper cell balance in ESRD
As discussed above, there is a complex interplay
of cytokines in patients with ESRD, with certain
cytokines, such as TNF-a and IL-6, having proinflam-
matory and proatherosclerotic actions, whereas other
cytokines, notably IL-10, having anti-inflammatory and
antiatherosclerotic actions. A major question is what
drives an individual to have one response versus the
other, and whether proactive measures can be done to
reset cytokine balance. While numerous cells express cy-
tokines, one of the major systems driving their expres-
sion is the immune system, particularly the T-helper (CD4
or Th) cell, which to a large extent will regulate the cy-
tokine expression in various tissues. Based on their cy-
tokine profile, CD4 T-helper cells are classified into two
distinct types; type-1 (Th1) and type-2 (Th2). Th1 cells are
involved in the innate cell-mediated immunity and pro-
duce several proinflammatory cytokines, notably TNF-a,
IL-12 and interferon-gamma (INF-c). Although Th2 cells
are involved in humoral immunity and produce cytokines,
such as IL-4 and IL-5, they also produce IL-6 and thus also
have a role in the systemic inflammatory response. Finally,
there is a T-regulatory cell (CD4+/CD25+) that produces
IL-10 and is capable of down-regulating both the Th1 and
Th2 response. The importance of this association is high-
lighted by recent studies that suggest Th1 responses may
be actively involved in lesion formation in atherosclerosis
whereas Th2 responses have a lesser, although still im-
portant role [99]. It has been suggested that the balance
between pro- and anti-inflammatory cytokines is decisive
for the progression of the atherosclerotic lesion [100]. The
control of Th1/Th2 responses by T-regulatory cells may
be important in suppressing atherosclerosis, as evidenced
by a study in IL-10 knockout mice [101].
It is not yet known whether the expression of the three
cytokines discussed; IL-10, IL-6, and TNF-a, may affect
the activation of the T-regulatory, Th2 and Th1 cells in
ESRD patients. Thus, this will be an important area to
study. Characteristics that could influence the type and
degree of T-cell response in the ESRD patient could in-
clude genetic factors (such as polymorphisms), the pres-
ence of a vast number of different diseases, and recent
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Fig. 5. Oversimplified sketch showing how the balance between Th1 and Th2 may be affected by genetic factors, retention of uremic solutes,
immunomodulatory drugs [such as statins, glitazones and angiotensin-converting enzyme (ACE) inhibitors, environmental factors (such as infections,
social hygiene and stress), and a vast number of diseases. IL is interleukin; TNF is tumor necrosis factor; INF is interferon; GN is glomerulonephritis;
IDDM is insulin dependent diabetes mellitus; ESRD is end-stage renal disease.
exposure to infections/antigens that could modulate the
immune response (Fig. 5). Indeed, a gradual change in the
frequency of childhood infection has occurred in indus-
trialized western countries, affected by the introduction
of indoor plumbing in the nineteenth century, antibiotics
in the middle of the twentieth century, and cleaner homes
at the end of the twentieth century. On the other hand, in
developing countries, exposure to crowded houses with
poor sanitary conditions, less access to antibiotics, and in-
efficient vaccination programs lead to a higher prevalence
of infections occurring in the early phase of life. Infections
(specifically through endotoxins) are potent inducers of
IL-12 and INF-c, which are cytokines that stimulate Th1-
mediated immunity, and also decrease the production of
Th2 inflammatory cytokines, such as IL-4, IL-5, and IL-
13 [102]. Moreover, a decrease in antigenic stimulation
related to the reduction of childhood infections results
in a decrease in the levels of regulatory cytokines, par-
ticularly IL-10. According to this “hygiene hypothesis”
[103], early avoidance of microbial exposure could ex-
plain on one hand the increase of Th2 dominant diseases,
such as allergy [102], and on the other a decrease in Th1-
dominant diseases, such as atherosclerosis. In addition, it
could be hypothesized that patients with a predominant
Th1 phenotype will be more prone to complications of
CKD, such as faster progression to ESRD, development
of malnutrition, and accelerated atherosclerosis [104].
Thus, it could be speculated that the dramatic increase
in CVD in developing countries could be partly related
to this phenomenon [105]. Uremia itself, while generally
suppressing T-cell function [106], is also associated with
altered Th balance. Most studies demonstrate Th1 pre-
dominance [107, 108], although there are also some re-
ports of Th2 predominance [109]. Clearly, further studies
are needed to determine if alterations in Th balance may
predispose to alterations in cytokines that might be re-
sponsible for the increased CVD risk in ESRD.
We believe that a closer surveillance of the Th1/Th2
balance might be helpful in disease activity monitoring
and will perhaps also help in the design of more adequate
therapeutic strategies. Indeed, recent evidence suggests
that not only classic immunomodulatory drugs, such as
1226 Stenvinkel et al: IL-10, IL-6, and TNF-a: Central factors in the cytokine network of uremia
cyclosporine and cortisone, affect Th balance but also
that other, less potent immunomodulating drugs, such as
angiotensin-converting enzyme (ACE) inhibitors [110],
peroxisome proliferators-activated receptors (PPAR) ac-
tivators [111], and statins [112], may affect T-cell activa-
tion signals in ESRD (vide infra). However, although the
concept of Th balance may be attractive and helpful in
order to understand the nature of immunologic disease
processes, such as atherosclerosis, it should be empha-
sized that not all immunologists agree on the validity of
this concept. Moreover, it must be remembered that there
may be a significant overlap between Th1 and Th2 activity
and that the Th balance may shift as many disease pro-
cesses progress, such as in hepatitis C and vasculitis. Thus,
Th balance should always be interpreted with caution.
VASCULAR CALCIFICATION AND
INFLAMMATION
Although pro- and anti-inflammatory cytokines may
affect a number of pathophysiologic events leading to ac-
celerated atherosclerosis (discussed above) the roles of
inflammation and cytokine dysregulation in the vascu-
lar calcification process have not been much discussed
at length. However, a new inflammatory basis for the
pathomechanisms of extraosseous Ca × PO4 precipita-
tion has emerged following recent advances in the under-
standing of the regulation of calcification processes, bone
turnover, and osteoporosis in addition to novel epidemio-
logic insights. Vascular calcification is extremely common
in the uremic population and is a central characteristic of
the progressive atherosclerosis observed in dialysis pa-
tients [113]. The presence of vascular and valvular calci-
fication has been shown to be associated with poor sur-
vival in both hemodialysis [113] and peritoneal dialysis
[114] patients. Two major types of vascular calcification
occur in the vessel wall (i.e., intimal and medial calcifica-
tion). Intimal calcifications are plaque calcifications and
thus develop in a local inflammatory environment. Me-
dial calcifications, on the other hand, do not show signs
of inflammation in their vicinity, but regulatory factors
involved may be influenced by systemic inflammatory re-
actions. Major progress in the understanding of the cal-
cification process was made possible by tedious in vitro
studies of vascular smooth muscle cells (VSCM) show-
ing that these cells may undergo phenotypic differentia-
tion processes into osteoblast-like cells. Jono et al [115]
demonstrated that in order to cause extraosseus calcifica-
tion hyperphosphatemia required active intracellular up-
take of PO4 and the de novo formation of matrix vesicles
by VSCM in vitro. Furthermore, the intracellular rise in
PO4 concentration caused a phenotypic switch of VSCM,
leading to the expression of bone-related transcription
factors and proteins, such as alkaline phosphatase, osteo-
pontin, and osteocalcin [115]. Importantly, an inflamma-
tory environment seems to cause identical pathophysi-
ologic changes within the vessel wall. Tintut et al [88]
showed osteogenic differentiation of cultured VSCM fol-
lowing stimulation with TNF-a. Histologic evaluation of
calcified vessels meanwhile confirmed that differentiated
bone structures form within blood vessels [116].
A central point in the understanding of extraosseous
calcification is related to the fact that even normal serum
calcium and PO4 concentrations are several orders of
magnitude above their solubility product, meaning that
calcification inhibitors are critical to prevent calcium
and PO4 precipitation in vivo. At least two calcification
inhibitors show a relationship to inflammation; fetuin-
A and osteoprotegerin (OPG). Fetuin-A (a2-Heremans
Schmid glycoprotein) (AHSG) is a 62 kD protein syn-
thesized in hepatocytes that is present in normal serum
concentrations as high as 0.5 to 1.0 g/L. Importantly,
fetuin-A reacts as a negative acute-phase protein (i.e.,
expression is suppressed in situations of inflammation
facilitating predisposition toward extraosseous Ca x
PO4 precipitation) [117]. Although TNF-a and IL-6
are among the cytokines potentially capable of down-
regulating hepatic fetuin-A expression it should also be
noted that fetuin-A may have important functions in in-
flammation, such as limitation of cytokine production
by macrophages and protection against TNF [118]. In a
cross-sectional study we measured fetuin-A levels in 312
prevalent hemodialysis patients and found that patients
with low fetuin-A serum levels showed a significantly
poorer survival than those with normal or high-normal
values [9]. As expected, patients with low fetuin-A levels
had significantly elevated CRP levels suggesting a direct
relationship between inflammation and down-regulation
of the extracellular calcification inhibitory capacity. These
findings were recently confirmed by us in 258 incident
ESRD patients starting dialysis treatment showing that
low fetuin-A levels was associated with malnutrition, in-
flammation, and atherosclerosis (carotid plaques) as well
as with increased cardiovascular and all-cause mortality
[119]. As elevated CRP is a valid predictor of cardio-
vascular events and death in the dialysis population [10],
a pathomechanistic relationship between inflammation
and vascular calcification processes seems appropriate
and justified.
Another interesting new aspect in the context of in-
flammation and vascular calcification is based on observa-
tions that osteoporosis and vasculopathy are often linked
via inflammatory pathomechanisms. The OPG/RANKL
(receptor activator of NF-jB) system may play a cen-
tral role in the regulation of bone turnover, and in cal-
cification processes at extra-osseous sites [120]. OPG is
a member molecule of the TNF receptor superfamily
and serves as a decoy receptor for RANKL, which ac-
cordingly belongs to the TNF superfamily. RANKL di-
rectly induces osteoclast differentiation and maturation,
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and OPG counteracts this action by binding RANKL
prior to receptor interaction [120]. OPG knockout
animals develop osteoporosis as well as significant calci-
fications of aorta and renal arteries [121]. As serum OPG
levels recently were associated with both CRP and the
extent of vascular calcification in hemodialysis patients
[122] it could be speculated that the observed increase of
serum OPG may be a compensatory protective response
to the progression of vascular calcification. Clearly, fur-
ther clinical studies are needed to elucidate the associa-
tion between progressive vascular calcification and this
interesting calcification inhibitor. As the RANKL/OPG
signaling pathway seems central to the processes regulat-
ing both vascular calcification and bone turnover [123]
it is of interest that London et al [124] recently demon-
strated that arterial calcification is associated with low
bone activity in ESRD. Thus, further studies are nec-
essary to unravel the detailed role of a stimulated im-
mune system as a central factor in the pathogenesis of
vessel wall calcifications and adynamic bone disease in
the presence of a uremic milieu. In this context, it may
well be advisable to also move one step beyond uremia
and focus on primary inflammatory diseases to gain a
better understanding of vascular calcification processes.
Indeed, Asanuma et al [125] documented an increased
coronary calcification burden in SLE patients. Extrapo-
lating from such data it could be speculated that effective
anti-inflammatory and anticytokine management may ex-
ert significant vasculoprotective effects.
ANTICYTOKINE THERAPY IN RENAL DISEASE
Given the strongly documented associations between
proinflammatory cytokines and complications common
in ESRD, such as vascular calcification and wasting, both
general and targeted anticytokine treatment strategies
have been proposed for this patient group (Table 3). It
is notable that several commonly used drugs possess sig-
nificant anti-inflammatory effects. It is now evident that
statins not only inhibit cholesterol synthesis but also have
anti-inflammatory actions. Randomization to pravastatin
after myocardial infarction resulted in significant reduc-
tions in CRP [126] and a recent study showed that ator-
vastatin inhibits IL-6 secretion in adipocytes possibly
through up-regulating PPAR-c activity [127]. Accord-
ingly, as statins may be immunoprotective by promoting
Th2 development [112] and inducing Th2 cytokines, such
as IL-4, IL-5, and IL-10, they may have a therapeutic
potential not only in atherosclerosis but also in the treat-
ment of other inflammatory diseases [128]. As it recently
was shown that statins induce SOCS in macrophages this
may be yet another mechanism by which statins down-
regulate activated macrophages [129]. It has been demon-
strated that statins, in addition to its lipid-lowering effect,
have an anti-inflammatory effect also in hemodialysis pa-
tients [130].
Table 3. Examples of life-style modification, drugs with secondary
anticytokine effect, and selected targeted anticytokine treatments that
could be considered in selected end-stage renal disease (ESRD)
patients
Life-style modification
Weight reduction
Exercise training
Diet (soy, berries, fruit and fish)
Drugs that may have secondary
anticytokine effects
Current indication
3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors
Dyslipidemia
Angiotensin-converting enzyme
inhibitors
Hypertension, congestive
heart failure
Gamma-tocopherol Vitamin supplementation
N-acetylcysteine Bronchitis
Nonsteroidal anti-inflammatory
drugs
Pain
Peroxisome proliferator-activated
receptor-c activators
Diabetes mellitus
Eicosapentotenic acid –
Megestrol acetate Appetite stimulant
Testosterone Hypogonadism
Targeted anticytokine treatment
strategies
Current indication
Thalidomide Myeloma, leprosy
Pentoxifylline Peripheral vascular disease
Etanercept Rhematoid arthritis,
Crohn’s disease
Infliximab Rheumatoid arthritis,
Crohn’s disease
Anakinra Rheumatoid arthritis
Also ACE inhibitors have anti-inflammatory proper-
ties and it could be speculated that some of the benefi-
cial effects of this class of drug may be related to such
activities. Indeed, Brull et al [131] noted that ACE in-
hibitor treatment is associated with a reduction in IL-6
response to coronary artery graft surgery and we have
found lower plasma levels of TNF-a and CRP in ESRD
patients treated by ACE inhibitors [132]. Recently, we re-
ported impaired cytokine-induced NF-jB translocation
from the cytoplasm to the nucleus in captopril preincu-
bated monocytes [133]. A recent study of 1920 CHF pa-
tients from the SOLVD trial demonstrated that treatment
with an ACE inhibitor reduced the risk of weight loss
[134], supporting the hypothesis of relationships among
wasting, the renin-angiotensin system, and inflammation.
Glitazones (PPAR-c activators) is another group of
drugs that have been shown to inhibit the activation of
inflammatory response genes, and promote an immune
deviation away from Th1 toward Th2 cytokine produc-
tion [111]. Thus, glitazones may have therapeutic appli-
cations in inflammatory diseases. Interestingly, various
antioxidative treatment strategies may also have anti-
inflammatory effects [8]. Indeed, both vitamin E and
N-acetylcysteine, two drugs that may inhibit proinflam-
matory cytokine release [135, 136] and improve endothe-
lial dysfunction [137, 138] have been shown to both
reduce cardiovascular events in dialysis patients [139,
140]. On the other hand, a recent evaluation of the HOPE
trial showed no benefit of vitamin E on cardiovascular
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outcomes in patients with mild-to-moderate CKD [141].
Megestrol acetate, a steroid-like progestagen used for
treatment of advanced breast cancer, showed increased
appetite as an unexpected side-effect [142]. Subsequently,
orexigenic and weight gaining effects of megestrol acetate
has been attributed to anticytokine properties of the drug,
which is now regularly used against cancer and human
immunodeficiency virus (HIV) cachexia. However, the
drug has not been extensively tested under other clinical
conditions and only few uncontrolled studies have been
examining the use of megestrol acetate in ESRD.
Sex hormones may also be important for atheroprotec-
tion as men with low testosterone levels as well as women
with low estrogens are at increased risk of CVD. The re-
ported ability of sex hormones to interfere with cytokine
production by repression of IL-6 mRNA may contribute
to the protective effects [143]. Anti-inflammatory and car-
dioprotective effects of the omega-3 fatty acids of fish
oil, mainly eicosapentaenoic acid, are well recognized.
Based on a study by Kutner et al [144] that found dial-
ysis patients who reported fish consumption were 50%
less likely to die during the observation period, and the
fact that dietary fish oil decreases CRP and IL-6 levels
in nonrenal subjects [145], the potential beneficial effects
of this basic form of anticytokine therapy certainly mer-
its further investigation in ESRD patients. Also, a num-
ber of other nutritional interventions, such as fiber-rich
food, nuts, probiotics, and diets low in advanced glycation
end-products may have anti-inflammatory properties and
should be evaluated in ESRD patients [146]. Finally,
given the documented associations between proinflam-
matory cytokines and life-style factors [147], life-style
modification may be an important component in nor-
malizing dysregulated cytokine system activity in ESRD
patients.
Is there a role for targeted anticytokine treatment
strategies in ESRD?
Although life-style modification and unspecific anti-
cytokine treatment strategies should be cornerstones in
the treatment of dysregulated cytokine system activ-
ity in ESRD, targeted anticytokine treatment strategies,
which have been tested patients with other inflamma-
tory states, also may be of interest in ESRD patients
(Table 3). Thalidomide, a drug with immunomodula-
tory, anti-inflammatory and antiangiogenic properties,
exerts its therapeutic effects through the modulation of
cytokines, especially TNF-a. As thalidomide induces a
Th2 response and has been associated with weight gain
in other wasted patient groups, such as those with HIV
or tuberculosis [148], and one recent study reported
that it is capable of inhibiting early atherosclerosis in
ApoE-deficient mice [149], it would be of interest to
test the effects of this drug in ESRD patients. Pen-
toxifylline, a phosphodiesterase inhibitor, was recently
shown to reduce TNF-a expression by >50% and to im-
prove hemoglobin levels in hemodialysis patients with
erythropoietin-resistant anemia [150]. Other anti-TNF
treatment strategies, such as TNF-receptor blockade
(etanercept) and antibody treatment against TNF (in-
fliximab) have recently been shown to be effective in
inflammatory disorders, such as rheumatoid arthritis
[151] and inflammatory bowel disease. The medical and
commercial success of targeted anti-TNF treatment in
rheumatoid arthritis has prompted researchers to con-
sider anticytokine treatment strategies in other patients
with inflammatory diseases, such as CHF patients. How-
ever, the value of anticytokine therapy in the man-
agement of patients with CHF is highly controversial.
Although some initial anti-TNF studies suggested some
hemodynamic and clinical benefits, subsequent large-
scale studies were stopped prematurely because of
increased mortality [152]. Thus, although the use of anti-
TNF treatment would be logical in inflamed and mal-
nourished ESRD patients with elevated serum levels of
TNF-a, available toxicity data should caution clinicians
against liberal use of anti-TNF agents to interfere with
very basic physiologic events until large randomized trials
have been conducted to prove their efficacy in this patient
group. Still, anti-TNF-a strategies may even counteract
vascular calcification by either directly acting on the ves-
sel wall or by potentially down-regulating fetuin-A ex-
pression, respectively [153].
The role of the inflammation varies with type of dis-
ease. If (i.e., in rheumatoid arthritis and Crohn’s disease)
inflammation is a primary etiologic event proximal ma-
nipulation of the inflammatory pathways is likely to be
beneficial. On the other hand, inflammation might be
purely adaptive as in most acute illnesses (e.g., infections)
and here interference should not be attempted. It should
be noted that the cytokine levels encountered in ESRD
are relatively low compared to the ones usually found in
infectious complications, such as sepsis. However, an ini-
tially adaptive inflammatory response may under chronic
conditions become partly maladaptive, as might be the
case with most malignancies, obstructive pulmonary dis-
eases, CHF, and probably with ESRD. In such disorders,
inflammation may be viewed as a two-edged sword where
the response may have both negative and positive ef-
fects on disease progression. Indeed, there is a growing
body of evidence suggesting that neutralization of TNF-a
may be associated with an increased risk of oppor-
tunistic infections, such as Mycobacterium tuberculosis
[154]. On the other hand, no activation of tuberculosis or
other opportunistic infections has so far been reported
following treatment with an IL-1 receptor antagonist
(IL-1RA) (anakinra) in five placebo-controlled trials of
rheumatoid arthritis patients [155]. In fact, in the rheuma-
toid arthritis patient population, IL-1RA treatment is
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well tolerated with a favorable safety profile [155]. Thus,
given the putative role of a dysregulated cytokine sys-
tem activity in causing malnutrition and atherosclerosis
in ESRD patients and the salutary effects on functional
status in rheumatoid arthritis patients following IL-1RA
treatment placebo-controlled trials with IL-1RA could
be proposed in ESRD patients with inflammation. As
administration of specific IL-1RA attenuates some, but
not all, of the metabolic responses secondary to systemic
infection or endotoxins and prevents sepsis-induced in-
hibition of protein synthesis in rats [156], and decrease
biomarkers of inflammation in other inflamed patient
groups [157], there are pathophysiologic reasons to be-
lieve that carefully selected ESRD patients could ben-
efit from such a treatment. Indeed, an interesting link
between stimulus-dependent variability in IL-1RA syn-
thesis by mononuclear cells and clinical outcome of
hemodialysis patients have been reported [158]. Ther-
apeutic application of IL-10 might also be suggested in
ESRD patients, particularly since this cytokine has ef-
fects on a broad range of proinflammatory factors. Clin-
ical trials in patients with chronic inflammatory bowel
disease [159], rheumatoid arthritis, or psoriasis showed
that the substance is well tolerated, however, not univer-
sally effective. For still unresolved reasons, only psoriasis
seems to improve with IL-10. As bioavailability of the cy-
tokine in the relevant compartment may be one reason,
its usefulness for systemic inflammation in ESRD should
be tested clinically.
Finally, inflammation-dependent cardiovascular cal-
cification may also represent a modifiable risk factor
that could be considered as an important therapeutic
target in ESRD. As briefly pointed out above, anticy-
tokine therapies, as well as optimized dialysis modali-
ties, may be candidates to suppress osteogenic differenti-
ation in the vasculature and to influence hepatic fetuin-A
synthesis. Specific stimulation of hepatic fetuin-A syn-
thesis could be an even more elegant way to defend
against vascular calcification. Indeed, recent studies re-
vealed a glucocorticoid-response element in the fetuin-A
promotor (Jahnen-Dechent W; personal communica-
tion). More specific means to up-regulate synthesis of
this calcification inhibitor than steroid treatment may
hopefully become feasible by a deeper understanding of
promotor regulation. Last, since OPG is likely to pos-
sess calcification inhibitory capacity, the development of
anti-osteoporotic OPG peptidomimetics may facilitate
protective effects with regard to the vascular wall cal-
cifications [160].
CONCLUSION
Although the successful introduction of dialysis in
the 1960s has increased life expectancy in patients with
ESRD the mortality rate is still unacceptably high, due
primary to a process of inflammation-associated acceler-
ated atherosclerosis. The accelerated atherosclerotic pro-
cess of ESRD may involve several interrelated processes,
such as oxidative stress, endothelial dysfunction, vascu-
lar calcification, and inflammation, all amenable to inter-
vention. No doubt, the explosion of new knowledge on
the central role of a dysregulated cytokine and Th sys-
tem activity has opened new and exciting opportunities
for nephrologists to manage and prevent CVD and wast-
ing in this diseased patient group. However, to make use
of these new insights we need to better understand the
complex interplay and balance between pro- and anti-
inflammatory mediators in the context of a uremic mi-
lieu, which may have fundamental effects on the cytokine
network—some good, some bad, and some ugly.
Reprint requests to Peter Stenvinkel, M.D., Ph.D., Department of Re-
nal Medicine, K56, Karolinska University Hospital at Huddinge, 141 86
Stockholm, Sweden.
E-mail: peter.stenvinkel@klinvet.ki.se
REFERENCES
1. QUINTON W, DILLARD D, SCRIBNER BH: Cannulation of blood ves-
sels for prolonged hemodialysis. Trans Am Soc Artif Intern Organs
6:104–113, 1960
2. LINDNER A, CHARRA B, SHERRARD DJ, SCRIBNER BH: Accelerated
atherosclerosis in prolonged maintenance haemodialysis. N Engl
J Med 290:697–701, 1974
3. EKNOYAN G, BECK GJ, CHEUNG AK, et al: Effect of dialysis dose
and membrane flux in maintenance hemodialysis. N Engl J Med
347:2010–2019, 2002
4. PANIAGUA R, AMATO D, VONESH E, et al: Effects of increased
peritoneal clearances on mortality rates in peritoneal dialysis:
ADEMEX, a prospective, randomized, controlled trial. J Am Soc
Nephrol 13:1307–1320, 2002
5. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of car-
diovascular disease in chronic renal failure. Am J Kidney Dis 32
(Suppl 5):S112–S119, 1998
6. BUZELLO M, TORNIG J, FAULHABER J, et al: The apolipoprotein E
knockout mouse: A model documenting accelerated atherogenesis
in uremia. J Am Soc Nephrol 14:311–316, 2003
7. PAPANICOLAOU DA, VGONTZAS AN: Interleukin-6: The endocrine
cytokine. J Clin Endocrin Metab 85:1331–1333, 2000
8. STENVINKEL P, PECOITS-FILHO R, LINDHOLM B: Coronary artery dis-
ease in end-stage renal disease—No longer a simple plumbing
problem. J Am Soc Nephrol 14:1927–1939, 2003
9. KETTELER M, BONGARTZ P, WESTENFELD R, et al: Association of
low fetuin-A (AHSG) concentrations in serum with cardiovascular
mortality in patients on dialysis: A cross-sectional study. Lancet
361:327–333, 2003
10. STENVINKEL P, ALVESTRAND P: Inflammation in end-stage renal dis-
ease: Sources, consequences and therapy, Semin Dial 15:330–338,
2002
11. ALLON M, DEPNER TA, RADEVA M, et al: Impact of dialysis dose and
membrane on infection-related hospitalization and death: Results
of the HEMO study. J Am Soc Nephrol 14:1863–1870, 2003
12. MATAS AJ, SIMMONS RL, KJELLSTRAND CM, et al: Increased inci-
dence of malignancy during chronic renal failure. Lancet 1:883–
886, 1975
13. DINARELLO CA: Cytokines and biocompatibility. Blood Purif
8:208–213, 1990
14. GLORIEUX GL, DHONDT AW, JACOBS P, et al: In vitro study of the
potential role of guanidines in uremia-related atherogenesis and
infection. Kidney Int 65:2184–2192, 2004
15. DOHERTY TM, ASOTRA K, FITZPATRICK LA, et al: Calcification in
atherosclerosis: bone biology and chronic inflammation at the ar-
terial crossroads. Proc Natl Acad Sci USA 100:11201–11206, 2003
1230 Stenvinkel et al: IL-10, IL-6, and TNF-a: Central factors in the cytokine network of uremia
16. MEISEL C, VOGT K, PLATZER C, et al: Differential regulation of
monocytic tumor necrosis factor alpha and interleukin-10 expres-
sion. Eur J Immunol 26:1580–1586, 1996
17. MORITA Y, YAMAMURA M, KASHIHARA N, MAKINO H: Increased
production of interleukin-10 and inflammatory cytokines in blood
monocytes of hemodialysis patients. Res Commun Mol Pathol
Pharmacol 98:19–33, 1997
18. BRUNET P, CAPO C, DELLACASAGRANDE J, et al: IL-10 synthesis and
secretion by peripheral blood mononuclear cells in haemodialysis
patients. Nephrol Dial Transpl 13:1745–1751, 1998
19. OLSZYNA DP, PAJKRT D, LAUW FN, VAN DEVENTER SJ: Interleukin
10 inhibits the release of CC chemokines during human endotox-
emia. J Infect Dis 181:613–620, 2000
20. DE WAAL MALEFYT R, HAANEN J, SPITS H, et al: Interleukin 10
(IL-10) and viral IL-10 strongly reduce antigen-specific human T-
cell proliferation by diminishing the antigen-presenting capacity of
monocytes via downregulation of class II major histocompatibility
complex expression. J Exp Med 174:915–924, 1991
21. WANG P, WU P, SIEGEL MI, et al: Interleukin (IL)-10 inhibits nuclear
factor kappa B (NF kappaB) activation in human monocytes. J Biol
Chem 270:9558–9563, 1995
22. ESKDALE J, GALLAGHER G: A polymorphic dinucleotide repeat in
the human IL-10 promoter. Immunogenetics 42:444–445, 1995
23. GIRNDT M, SESTER U, SESTER M, et al: The interleukin-10 promo-
tor genotype determines clinical immune function in hemodialysis
patients. Kidney Int 60:2385–2391, 2001
24. KO¨HLER H, ARNOLD WC, RENSCHIN G, et al: Active hepatitis B vac-
cination of dialysis patients and medical staff. Kidney Int 25:124–
128, 1984
25. GIRNDT M, KOHLER H, SCHIEDHELM-WEICK E, et al: Production
of interleukin-6, tumour necrosis factor alpha and interleukin-
10 in vitro correlates with the clinical immune defect in chronic
hemodialysis patients. Kidney Int 47:559–565, 1995
26. ROSS R: Atherosclerosis: An inflammatory disease. N Engl J Med
340:115–126, 1999
27. SONG S, LING-HU H, ROEBUCK KA, et al: Interleukin-10 inhibits
interferon-gamma-induced intercekllular adhesion molecule-1
gene transcription in human monocytes. Blood 89:4461–4469, 1997
28. KUGA S, OTSUKA T, NIIRO H, et al: Suppression of superoxide anion
production by interleukin-10 is accompanied by a downregulation
of the genes for subunit proteins of NADPH oxidase. Exp Hematol
24:151–157, 1996
29. LACRAZ S, NICOD LP, CHICHEPORTICE R, et al: IL-10 inhibits metal-
loproteinase and stimulate TIMP-1 production in human mononu-
clear phagocytes. J Clin Invest 96:2304–2310, 1995
30. VON DER THUSEN JH, KUIPER J, FEKKES ML, et al: Attenuation of
atherogenesis by systemic and local adenovirus-mediated gene
transfer of interleukin-10 in LDLr−/− mice. FASEB J 15:2730–
2732, 2001
31. SMITH DA, IRVING SD, SHELDON J, et al: Serum levels of the antiin-
flammatory cytokine interleukin-10 are decreased in patients with
unstable angina. Circulation 104:746–749, 2001
32. HEESCHEN C, DIMMELER S, HAMM CW, et al: Serum level of the anti-
inflammatory cytokine interleukin-10 is an important prognostic
determinant in patients with acute coronary syndromes. Circula-
tion 107:2109–2114, 2003
33. WAEHRE T, HALVORSEN B, DAMAS JK, et al: Inflammatory imbal-
ance between IL-10 and TNF-alpha in unstable angina; potential
plaque stabilizing effects of IL-10. Eur J Clin Invest 32:803–810,
2002
34. GIRNDT M, KAUL H, SESTER U, et al: Anti-inflammatory
interleukin-10 genotype protects dialysis patients from cardiovas-
cular events. Kidney Int 62:949–955, 2002
35. KOCH W, KASTRATI A, BOTTIGER C, et al: Interleukin-10 and tumor
necrosis factor gene polymorphisms and risk of coronary artery dis-
ease and myocardial infarction. Atherosclerosis 159:137–144, 2001
36. TAGA T, HIBI M, HIRATA Y, et al: Interleukin-6 triggers the associ-
ation of its receptor with a possible signal transducer, gp130. Cell
58:573–581, 1989
37. JONES SA, HORIUCHI S, TOPLEY N, et al: The soluble interleukin 6
receptor: Mechanisms of production and implications in disease.
FASEB J 15:43–58, 2001
38. STENVINKEL P, BARANY P, HEIMBU¨RGER O, et al: Mortality, malnu-
trition and atherosclerosis in end-stage renal disease: What is the
role of interleukin-6? Kidney Int 61:S103–S108, 2002
39. PECOITS-FILHO R, HEIMBU¨RGER O, BA´RA´NY P, et al: Associations
between circulating inflammatory markers and residual renal func-
tion in CRF patients. Am J Kidney Dis 41:1212–1218, 2003
40. DESCAMPS-LATSCHA B, HERBELIN A, NGUYEN AT, et al: Balance
between IL-1b , TNF-a, and their specific inhibitors in chronic renal
failure and maintenance dialysis. J Immunol 154:882–892, 1995
41. POOLE S, BIRD TA, SELKIRK S, et al: Fate of injected interleukin
1 in rats: Sequestration and degradation in the kidney. Cytokine
2:416–422, 1990
42. BOLTON CH, DOWNS LG, VICTORY JGG, et al: Endothelial dys-
function in chronic renal failure: Roles of lipoprotein oxidation
and pro-inflammatory cytokines. Nephrol Dial Transplant 16:1189–
1197, 2001
43. SHARMA R, BOLGER AP, LI W, et al: Elevated circulating levels
of inflammatory cytokines and bacterial endotoxin in adults with
congenital heart disease. Am J Cardiol 92:188–193, 2003
44. WOLLERT KC, DREXLER H: The role of interleukin-6 in the failing
heart. Heart Fail Rev 6:95–103, 2001
45. SATO Y, TAKATSU Y, KATAOKA K, et al: Serial circulating concentra-
tions of C-reactive protein, interleukin (IL)-4, and IL-6 in patients
with acute left heart decompensation. Clin Cardiol 22:811–813,
1999
46. ZOCCALI C, MALLAMCI F, TRIPEPI G, et al: Chlamydia pneumoniae
overall and cardiovascular mortality in end-stage renal disease
(ESRD). Kidney Int 64:579–584, 2003
47. NIESSNER A, KAUN C, ZORN G, et al: Polymorphic membrane pro-
tein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proin-
flammatory mediators in human endothelial cells in vitro by acti-
vation of the nuclear factor-kappaB pathway. J Infect Dis 188:108–
113, 2003
48. STENVINKEL P, HEIMBU¨RGER O, JOGESTRAND T: Elevated
interleukin-6 predicts progressive carotid atherosclerosis in dialy-
sis patients: Association to Chlamydia pneumoniae seropositivity.
Am J Kidney Dis 39:274–282, 2002
49. KATO A, TAKITA T, MARUYAMA Y, HISHIDA A: Chlamydial infection
and progression of carotid atherosclerosis in patients on regular
haemodialysis. Nephrol Dial Transplant 19:2539–2546, 2004
50. BONAFE M, OLIVIERI F, CAVALLONE L, et al: A gender-dependent
genetic predisposition to produce high levels of IL-6 is detrimental
for longevity. Eur J Immunol 31:2357–2361, 2001
51. MULLER-STEINHARDT M, HARTEL C, MULLER B, et al: The
interleukin-6 −174 promotor polymorhism is associated with long-
term kidney allograft survival. Kidney Int 62:1824–1827, 2002
52. TAKAHASHI T, KUBOTA M, NAKAMURA T, et al: Interleukin-6 gene
expression in peripheral mononuclear cells from patients under-
going hemodialysis or continuous ambulatory peritoneal dialysis.
Ren Fail 22:345–354, 2000
53. CAGLAR K, PENG Y, PUPIM LB, et al: Inflammatory signals associ-
ated with hemodialysis. Kidney Int 62:1408–1416, 2002
54. MOHAMED-ALI V, GOODRICK S, RAWESH A, et al: Subcutaneous adi-
pose tissue releases interleukin-6, but not tumour necrosis factor-a,
in vivo. J Clin Endocrin Metab 82:4196–4200, 1997
55. AXELSSON J, QURESHI AR, SULIMAN ME, et al: Truncal fat mass as a
contributor to inflammation in end-stage renal disease. Am J Clin
Nutr 80:1222–1229, 2004
56. PECOITS-FILHO R, BARANY B, LINDHOLM B, et al: Interleukin-6 and
its receptor is an independent predictor of mortality in patients
starting dialysis treatment. Nephrol Dial Transplant 17:1684–1688,
2002
57. KIMMEL PL, PHILLIPS TM, SIMMENS SJ, et al: Immunologic function
and survival in hemodialysis patients. Kidney Int 54:236–244, 1998
58. BOLOGA RM, LEVINE DM, PARKER TS, et al: Interleukin-6 pre-
dicts hypoalbuminemia, hypocholesterolemia, and mortality in
hemodialysis patients. Am J Kidney Dis 32:107–114, 1998
59. HARRIS TB, FERRUCCI L, TRACY RP, et al: Association of elevated
interleukin-6 and C-reactive protein levels with mortality in the
elderly. Am J Med 106:506–512, 1999
60. RIDKER PM, RIFAI N, STAMPFER MJ, HENNEKENS CH: Plasma
concentration of interleukin-6 and the risk of future myocardial
infarction among apparently healthy men. Circulation 101:1767–
1772, 2000
Stenvinkel et al: IL-10, IL-6, and TNF-a: Central factors in the cytokine network of uremia 1231
61. HUBER SA, SAKKINEN P, CONZE D, et al: Interleukin-6 exacer-
bates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol
19:2364–2367, 1999
62. VENUGOPAL SK, DEVARAJ S, YUHANNA I, et al: Demonstration that
C-reactive protein decreases eNOS expression and bioactivity in
human aortic endothelial cells. Circulation 106:1439–1441, 2002
63. YUDKIN JS, KUMARI M, HUMPHRIES SE, MOHAMED-ALI V: Inflam-
mation, obesity, stress and coronary heart disease: Is interleukin-6
the link? Atherosclerosis 148:209–214, 2000
64. NAWAWI H, OSMAN NS, ANNUAR R, et al: Soluble intercellular ad-
hesion molecule-1 and interleukin-6 levels reflect endothelial dys-
function in patients with primary hypercholesterolaemia treated
with atorvastatin. Atherosclerosis 169:283–291, 2003
65. BRUUN JM, LIHN AS, VERDICH C, et al: Regulation of adiponectin
by tissue-derived cytokines; in vivo and in vitro investigations in
humans. Am J Physiol Endocrinol Metab 285:E527–E533, 2003
66. ELHAGE R, CLAMENS S, BESNARD S, et al: Involvement of
interleukin-6 in atherosclerosis but not in the prevention of fatty
streak formation by 17beta-estradiol in apolipoprotein E-deficient
mice. Atherosclerosis 156:315–320, 2001
67. ROUBENOFF R: Catabolism of aging: Is it an inflammatory process?
Curr Opin Clin Nutr Metab Care 6:295–299, 2003
68. GOODMAN MN: Interleukin-6 induces skeletal muscle protein
breakdown in rats. Proc Soc Exp Biol Med 205:182–185, 1994
69. STRASSMAN G, FONG M, KENNEY JS, JACOB CO: Evidence for the
involvement of interleukin-6 in experimental cancer cachexia. J
Clin Invest 89:1681–1684, 1992
70. TSUJINAKA T, FUJITA J, EBISURI C, et al: Interleukin-6 receptor an-
tibody inhibits muscle atrophy and modulates proteolytic systems
in interleukin-6 transgenic mice. J Clin Invest 97:244–249, 1996
71. BARBIERI M, FERRUCI L, RAGNO E, et al: Chronic inflammation and
the effect of IGF-1 on muscle strength and power in older persons.
Am J Physiol Endocrinol Metab 284:E481–E487, 2003
72. PAYETTE H, ROUBENOFF R, JACQUES PF, et al: Insulin-like
growth factor-1 and interleukin 6 predict sarcopenia in very old
community-living men and women: The Framingham Heart Study.
J Am Geriatr Soc 51:1237–1243, 2003
73. ROUBENOFF R, HARRIS TB, ABAD LW, et al: Monocyte cytokine pro-
duction in an elderly population: Effect of age and inflammation.
J Gerontol A Biol Sci Med Sci 53:M20–M26, 1998
74. KAIZU Y, OHKAWA S, ODAMAKI M, et al: Association between in-
flammatory mediators and muscle mass in long-term hemodialysis
patients. Am J Kidney Dis 42:295–302, 2003
75. DINARELLO CA, ROUBENOFF RA: Mechanisms of loss of lean body
mass in patients on chronic dialysis. Blood Purif 14:388–394, 1996
76. KALANTAR-ZADEH K, BLOCK G, MCALLISTER CJ, et al: Appetite and
inflammation, nutrition, anemia and clinical outcome in hemodial-
ysis patients. Am J Clin Nutr 80:299–307, 2004
77. GRUNFELD C, ZHAO C, FULLER J, et al: Endotoxin and cytokines
induce expression of leptin, the ob gene product in hamsters. A
role for leptin in the anorexia of infection. J Clin Invest 97:2152–
2157, 1996
78. NAKANISHI I, MOUTABARRIK A, OKADA N, et al: Interleukin-8 in
chronic renal failure and dialysis patients. Nephrol Dial Transplant
9:1435–1442, 1994
79. BEMELMANS MH, GOUMA DJ, BUURMAN WA: Influence of nephrec-
tomy on tumor necrosis factor clearance in murine model. J Im-
munol 150:2007–2017, 1993
80. HESSION C, DECKER JM, SHERBLOM AP, et al: Uromodulin (Tamm-
Horsfall glycoprotein): A renal ligand for lymphokines. Science
237:1479–1484, 1987
81. YEH SS, SCHUSTER MW: Geriatric cachexia: The role of cytokines.
Am J Clin Nutr 70:183–197, 1999
82. AGUILERA A, CODOCEO R, SELGAS R, et al: Anorexigen (TNF-
alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma lev-
els in peritoneal dialysis (PD) patients. Their relationship with nu-
tritional parameters. Nephrol Dial Transplant 13:1476–1483, 1998
83. GUTTRIDGE DC, MAYO MW, MADRID LV, et al: NF-jB-induced
loss of MyoD messenger RNA: Possible role in muscle decay and
cachexia. Science 289:2363–2365, 2000
84. MITCH WE, DU J, BAILEY JL, PRICE SR: Mechanisms causing mus-
cle proteolysis in uremia: The influence of insulin and cytokines.
Miner Elect Metab 25:216–219, 1999
85. PLATA-SALAMA´N CR: Cytokines and anorexia: A brief overview.
Semin Oncol 25:64–72, 1998
86. STENVINKEL P, HEIMBU¨RGER O, PAULTRE F, et al: Strong associa-
tion between malnutrition, inflammation, and atherosclerosis in
chronic renal failure. Kidney Int 55:1899–1911, 1999
87. ZUCKERMAN SH, O’NEAL L: Endotoxin and GM-CSF-mediated
down-regulation of macrophage ApoE secretion is inhibited by
a TNF-specific monoclonal antibody. J Leukoc Biol 55:743–748,
1994
88. TINTUT Y, PATEL J, PARHAMI F, DEMER LL: Tumor necrosis factor-
a promotes in vitro calcification of vascular cells via the cAMP
pathway. Circulation 102:2636–2642, 2000
89. DE BIASE L, PIGNATELLI P, LENTI L, et al: Enhanced TNF alpha
and oxidative stress in patients with heart failure: effect of TNF
alpha on platelet O2− production. Thromb Haemost 90:317–325,
2003
90. BHAGAT K, VALLANCE P: Inflammatory cytokines impair
endothelium-dependent dilatation in human veins in vivo. Circu-
lation 96:3042–3047, 1997
91. FICHTSCHERER S, ROSENBERGER G, WALTER DH, et al: Elevated C-
reactive protein levels and impaired endothelial vasoreactivity in
patients with coronary heart disease. Circulation 102:1000–1006,
2000
92. HOTAMISLIGIL GS, ARNER P, CARO JF, et al: Increased adipose tissue
expression of tumor necrosis factor-alpha in human obesity and
insulin resistance. J Clin Invest 95:2409–2415, 1995
93. SVENUNGSSON E, FEI GZ, JENSEN-URSTAD K, et al: TNF-alpha: A link
between hypertriglyceridaemia and inflammation in SLE patients
with cardiovascular disease. Lupus 12:454–461, 2003
94. LEVINE B, KALMAN J, MAYER L, et al: Elevated circulating levels
of tumor necrosis factor in severe chronic heart failure. N Engl J
Med 323:236–241, 1990
95. RAUCHHAUS M, DOEHNER W, FRANCIS DP, et al: Plasma cytokine
parameters and mortality in patients with chronic heart failure.
Circulation 102:3060–3067, 2000
96. SCHINDLER R, KRAUTZIG S, LUFFT V, et al: Induction of interleukin-1
and interleukin-1 receptor antagonist during contaminated in-vitro
dialysis with white whole blood. Nephrol Dial Transplant 11:101–
108, 1996
97. BONNER JC, BRODY AR: Cytokine-binding proteins in the lung.
Am J Physiol 268:L869–L878, 1995
98. FUJIMOTO M, NAKA T: Regulation of cytokine signaling by SOCS
family molecules. Trends Immunol 24:659–666, 2003
99. DAVENPORT P, TIPPING PG: The role of interleukin-4 and
interleukin-12 in the progression of atherosclerosis in apolipopro-
tein E-deficient mice. Am J Pathol 163:1117–1125, 2003
100. FROSTEGA˚RD J, ULFGREN AK, NYBERG P, et al: Cytokine expres-
sion in advanced human atherosclerotic plaques: dominance of
pro-inflammatory (Th1) and macrophage-stimulating cytokines.
Atherosclerosis 145:33–43, 1999
101. CALIGIURI G, RUDLING M, OLLIVIER V, et al: Interleukin-10 de-
ficiency increases atherosclerosis, thrombosis, and low-density
lipoproteins in apolipoprotein E knockout mice. Mol Med 9:10–17,
2003
102. BACH JF: The effect of infections on susceptibility to autoimmune
and allergic diseases. N Engl J Med 47:911–920, 2002
103. STRACHAN DP: Hay fever, hygiene, and household size. Br Med J
299:1259–1260, 1989
104. LEINONEN M, SAIKKU P: Evidence for infectious agents in cardio-
vascular disease and atherosclerosis. Lancet Inf Dis 2:11–17, 2002
105. YUSUF S, REDDY S, OUNPUU S, ANAND S: Global burden of car-
diovascular diseases: Part II: Variations in cardiovascular disease
by specific ethnic groups and geographic regions and prevention
strategies. Circulation 104:2855–2864, 2001
106. MOSER B, ROTH G, BRUNNER M, et al: Aberrant T cell activation and
heightened apoptotic turnover in end-stage renal failure patients:
A comparative evaluation between non-dialysis, haemodialysis,
and peritoneal dialysis. Biochem Biophys Res Commun 308:581–
585, 2003
107. SESTER U, SESTER M, HAUK M, et al: T-cell activation follows Th1
rather than Th2 pattern in haemodialysis patients. Nephrol Dial
Transplant 15:1217–1223, 2000
108. ISHIZUKA T, NITTA K, YOKOYAMA T, et al: Increased serum levels
1232 Stenvinkel et al: IL-10, IL-6, and TNF-a: Central factors in the cytokine network of uremia
of interleukin-12 may be associated with Th1 differentiation in
hemodialysis patients. Nephron 90:503–504, 2002
109. LIBETTA C, RAMPINO T, DAL CANTON A: Polarization of T-helper
lymphocytes toward the Th2 phenotype in uremic patients. Am J
Kidney Dis 38:286–295, 2001
110. ODAKA CMT: Angiotensin-converting enzyme inhibitor captopril
prevents activation-induced apoptosis by interfering with T cell
activation signals. Clin Exp Immunol 121:515–522, 2000
111. SAUBERMANN LJ, NAKAJIMA A, WADA K, et al: Peroxisome
proliferator-activated receptor gamma agonist ligands stimulate
a Th2 cytokine response and prevent acute colitis. Inflamm Bowel
Dis 8:330–339, 2002
112. HAKAMADA-TAGUCHI R, UEHARA Y, KURIBAYASHI K, et al: Inhibi-
tion of hydroxymethylglutaryl-coenzyme a reductase reduces Th1
development and promotes Th2 development. Circ Res 93:948–
956, 2003
113. BLACHER J, GUERIN AP, PANNIER B, et al: Arterial calcifications,
arterial stiffness and cardiovascular risk in end-stage renal disease.
Hypertension 38:938–942, 2001
114. WANG A, WANG M, WOO J, et al: Cardiac valve calcification as
an important predictor for all-cause mortality and cardiovascu-
lar mortality in long-term peritoneal dialysis patients. J Am Soc
Nephrol 14:159–168, 2003
115. JONO S, MCKEE MD, MURRY CE, et al: Phosphate regulation of
vascular smooth muscle cell calcification. Circ Res 87:E10–E17,
2000
116. DEMER LL, TINTUT T: Mineral exploration: Search for the mech-
anism of vascular calcification and beyond: The 2003 Jeffrey M.
Hoeg Award Lecture. Arterioscler Thromb Vasc Biol 23:1739–
1743, 2003
117. LEBRETON JP, JOISEL F, RAOULT JP, et al: Serum concentration of
human alpha 2 HS glycoprotein during the inflammatory process:
Evidence that alpha 2 HS glycoprotein is a negative acute-phase
reactant. J Clin Invest 64:1118–1129, 1979
118. WANG H, ZHANG M, SODA K, et al: Fetuin protects the fetus from
TNF. Lancet 350:861–862, 1997
119. STENVINKEL P, WANG K, QURESHI AR, et al: Low fetuin-A levels
are associated with cardiovascular death: Impact of variations in
the gene encoding fetuin. Kidney Int (in press)
120. SCHOPPET M, PREISSNER KT, HOFBAUER LC: RANK ligand and os-
teoprotegerin: paracrine regulators of bone metabolism of bone
metabolism and vascular function. Arterioscler Thromb Vasc Bio
22:549–553, 2002
121. BUCAY N, SAROSI I, DUNSTAN CR, et al: Osteoprotegerin-deficient
mice develop early onset osteoporosis and arterial calcification.
Genes Dev 12:1260–1268, 1998
122. NITTA K, AKIBA T, UCHIDA K, et al: Serum osteoprotegerin levels
and the extent of vascular calcification in haemodialysis patients.
Nephrol Dial Transplant 19:1886–1889, 2004
123. JEFFCOATE W: Vascular calcification and osteolysis in diabetic
neuropathy-is RANK-L the missing link? Diabetologia 47:1488–
1492, 2004
124. LONDON GM, MARTY C, MARCHAIS SJ, et al: Arterial calcifications
and bone histomorphometry in end-stage renal disease. J Am Soc
Nephrol 15:1943–1951, 2004
125. ASANUMA Y, OESER A, SHINTANI AK, et al: Premature coronary-
artery atherosclerosis in systemic lupus erythematosus. N Engl J
Med 249:2407–2415, 2003
126. RIDKER PM, RIFAI N, PFEFFER MA, et al: Long-term effects of
pravastatin on plasma concentrations of C-reactive protein. Cir-
culation 100:230–235, 1999
127. ZHAO SP, ZHANG DQ: Atorvastatin reduces interleukin-6 plasma
concentration and adipocyte secretion of hypercholesterolemic
rabbits. Clin Chim Acta 336:103–108, 2003
128. NATH N, GIRI S, PRASAD R, et al: Potential targets of 3-hydroxy-3-
methylglutaryl coenzyme a reductase inhibitor for multiple scle-
rosis therapy. J Immunol 172:1273–1286, 2004
129. HUANG KC, CHEN CW, CHEN JC, LIN WW: Statins induce suppres-
sor of cytokine signaling-3 in macrophages. FEBS Lett 555:385–
389, 2003
130. VERNAGLIONE L, CRISTOFANO C, MUSCOGIURI P, CHIMIENTI S: Does
atorvastatin influence serum C-reactive protein levels in patients
on long-term hemodialysis? Am J Kidney Dis 43:471–478, 2004
131. BRULL DJ, SANDERS J, RUMLEY A, et al: Impact of angiotensin con-
verting enzyme inhibition on post-coronary artery bypass inter-
leukin 6 release. Heart 87:252–255, 2002
132. STENVINKEL P, ANDERSSON A, WANG T, et al: Do ACE-inhibitors
suppress tumor necrosis factor-a production in advanced chronic
renal failure? J Int Med 246:503–507, 1999
133. ANDERSSON P, CEDERHOLM T, JOHANSON A-S, PALMBLAD J: Capto-
pril impaired TNF-a induced IL-1b production in human mono-
cytes is associated with altered intracellular distribution of NFjB.
J Clin Lab Med 140:103–109, 2002
134. ANKER SD, NEGASSA A, COATS AJ, et al: Prognostic importance
of weight loss in chronic heart failure and the effect of treatment
with angiotensin-converting-enzyme inhibitors: An observational
study. Lancet 361:1077–1083, 2003
135. JIANG Q, ELSON-SCHWAB I, COURTEMANCHE C, AMES BN: Gamma-
tocopherol and its major metabolite, in contrast to alpha toco-
pherol, inhibit cycloxygenase activity in macrophages and epithe-
lial cells. Proc Natl Acad Sci 97:11494–11499, 2000
136. LAPPAS M, PERMEZEL M, RICE GE: N-acetyl-cysteine inhibits phos-
pholipid metabolism, proinflammatory cytokine release, protease
activity, and nuclear factor-kappaB deoxyribonucleic acid-binding
activity in human fetal membranes in vitro. J Clin Endocrin Metab
88:1723–1729, 2003
137. KINLAY S, FANG JC, HIKITA H, et al: Plasma alpha-tocopherol and
coronary endothelium-dependent vasodilator function. Circula-
tion 100:219–221, 1999
138. SCHOLZE A, RINDER C, BEIGE J, et al: Acetylcysteine reduces plasma
homocysteine concentration and improves pulse pressure and en-
dothelial function in patients with end-stage renal failure. Circula-
tion 109:369–374, 2004
139. BOAZ M, SMETANA S, WEINSTEIN T, et al: Secondary prevention with
antioxidants of cardiovascular disease in end stage renal disease
(SPACE): Randomised placebo-controlled trial. Lancet 356:1213–
1218, 2000
140. TEPEL M, VAN DER GIET M, STATZ M, et al: The antioxidant acetyl-
cysteine reduces cardiovascular events in patients with end-stage
renal failure. Circulation 107:992–995, 2003
141. MANN JFE, LONN EM, YI Q, et al: Effects of vitamin E on car-
diovascular outcomes in people with mild-to-moderate renal in-
sufficiency: Results of the HOPE Study. Kidney Int 65:1375–1380,
2004
142. TCHEKMEDYIAN N, TAIT N, MOODY M, et al: Appetite stimulation
with megestrol acetate in cachectic cancer patients. Semin Oncol
13(Suppl 4):37–43, 1986
143. ERSHLER WB, KELLER ET: Age-associated increased interleukin-
6 gene expression, late-life diseases, and frailty. Ann Rev Med
51:245–270, 2000
144. KUTNER NG, CLOW PW, ZHANG R, AVILES X: Association of fish
intake and survival in a cohort of incident dialysis patients. Am J
Kidney Dis 39:1018–1024, 2002
145. CIUBOTARU I, LEE YS, WANDER RC: Dietary fish oil decreases
C-reactive protein, interleukin-6 and tricylglycerol to HDL-
cholesterol ratio in postmenopausal women on HRT. J Nutr
Biochem 14:513–521, 2003
146. STENVINKEL P, LINDHOLM B, HEIMBU¨RGER O: Novel approaches in
an integrated therapy of inflammatory-associated wasting in end-
stage renal disease. Semin Dial 17:505–515, 2004
147. GIELEN S, ADAMS V, MOBIUS-WINKLER S, et al: Anti-inflammatory
effects of excercise training in the skeletal muscle of patients with
chronic heart failure. J Am Coll Cardiol 42:869–872, 2003
148. HASLETT PA: Anticytokine approaches to the treatment of
anorexia and cachexia. Semin Oncol 25 (Suppl 6):53–57, 1998
149. CHEW M, ZHOU J, DAUGHERTY A, et al: Thalidomide inhibits early
atherogenesis in apoE-deficient mice. APMIS (Suppl) 109:113–
116, 2003
150. COOPER A, MIKHAIL A, LETHBRIDGE MW, et al: Pentoxifylline
improves hemoglobin levels in patients with erythropoietin-
resistant anemia in renal failure. J Am Soc Nephrol 15:1877–1882,
2004
151. MAINI RN, FELDMANN M: Cytokine therapy in rheumatoid arthritis.
Lancet 348:824–825, 1996
152. ANKER SD: Imbalance of catabolic and anabolic pathways in
chronic heart failure. Scand J Nutr 46:3–10, 2002
Stenvinkel et al: IL-10, IL-6, and TNF-a: Central factors in the cytokine network of uremia 1233
153. BIRO L, DOMJAN G, FALUS A, et al: Cytokine regulation of the
acute-phase protein levels in multiple myeloma. Eur J Clin Invest
28:679–686, 1998
154. DINARELLO CA: Anti-cytokine therapy and infections. Vaccine
21:24–34, 2003
155. FLEISCHMANN RM: Addressing the safety of anakinra in pa-
tients with rheumatoid arthritis. Rheumatology 42 (Suppl 2):29–35,
2003
156. LLOYD CE, PALOPOLI M, VARY TC: Effect of central administration
of interleukin-1 receptor antagonist on protein synthesis is skeletal
muscle, kidney, and liver during sepsis. Metabolism 52:1218–1225,
2003
157. BRESNIHAN B, ALVARO-GARCIA JM, COBBY M, et al: Treatment of
rheumatoid arthritis with recombinant human interleukin-1 recep-
tor antagonist. Arthritis Rheum 41:2196–2204, 1998
158. BALAKRISHNAN VS, SCHMID CH, JABER BL, et al: Interleukin-1
receptor antagonists synthesis by peripheral blood mononuclear
cells: a novel predictor of morbidity among hemodialysis patients.
J Am Soc Nephrol 11:2114–2121, 2000
159. HERFARTH H, SCHOLMERICH J: IL-10 therapy in Crohn’s disease:
At the crossroads. Treatment of Crohn’s disease with the anti-
inflammatory cytokine interleukin 10. Gut 50:146–147, 2002
160. CHENG X, KINOSAKI M, TAKAMI M, et al: Disabling of receptor ac-
tivator of nuclear factor-kappaB (RANK) receptor complex by
novel osteoprotegerin-like peptidomimetics restores bone loss in
vivo. Biol Chem 279:8269–8277, 2004
